clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2023-1-1-49-55clinicaloncology-8Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASEИммунотерапия рака яичников: нестандартное решение — нестандартный ответOvarian cancer immunotherapy: non-standard solution — non-standard responshttps://orcid.org/0000-0002-8965-8364ГлузманМ. И.GluzmanM. I.

Глузман Марк Игоревич — 3.1.6, кандидат медицинских наук, доцент кафедры онкологии; заведующий химиотерапевтическим отделением (противоопухолевой лекарственной терапии) № 12 

AuthorID: 853558

199106, Санкт-Петербург, 21-я линия В.О., д. 8а

198255, Санкт-Петербург, пр. Ветеранов, д. 56

Gluzman Mark Igorevich — candidate of medical sciences, associate professor of the department of oncology; head of the chemotherapy department (antitumor drug therapy) No. 12

AuthorID 853558

St. Petersburg

lok2008@list.ruТюкавинаН. В.TyukavinaN. V.

Тюкавина Нина Владимировна — 3.1.6, заведующая отделением противоопухолевой лекарственной терапии

AuthorID 700523

197706, Санкт-Петербург, Сестрорецк, ул. Борисова, д. 9, лит. Б

Tyukavina Nina Vladimirovna — head of the department of antitumor drug therapy

AuthorID 700523

St. Petersburg

tyukavina@yandex.ruРуденкоД. С.RudenkoD.  S.

Руденко Дарья Сергеевна — 3.1.6, врач-онколог 

197706, Санкт-Петербург, Сестрорецк, ул. Борисова, д. 9, лит. Б

Rudenko Daria Sergeevna — oncologist

St. Petersburg

darya_r@bk.ruhttps://orcid.org/0000-0003-4447-9458ОрловаР. В.OrlovaR. V.

Орлова Рашида Вахидовна — 3.1.6, доктор медицинских наук, профессор, заведующий кафедрой онкологии; главный специалист по клинической онкологии 

 Author ID 401170

199106, Санкт-Петербург, 21-я линия В.О., д. 8а

198255, Санкт-Петербург, пр. Ветеранов, д. 56

Orlova Rashida Vakhidovna — Doctor of Medical Sciences, Prof., Head. Department of Oncology; Ch. clinical oncology specialist

Author ID 401170

St. Petersburg

orlova_rashida@mail.ruФГБОУ ВО «Санкт-Петербургский государственный университет»; СПб ГБУЗ «Городской клинический онкологический диспансер»РоссияSt. Petersburg State University; City Clinical Oncology DispensaryRussian FederationСПб ГБУЗ «Городская больница № 40»РоссияCity Hospital No. 40Russian Federation202325032024114955Copyright © Глузман М.И., Тюкавина Н.В., Руденко Д.С., Орлова Р.В., 20242024Глузман М.И., Тюкавина Н.В., Руденко Д.С., Орлова Р.В.Gluzman M.I., Tyukavina N.V., Rudenko D.S., Orlova R.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/8

Рак яичников является серьезной проблемой современной онкологии в связи с частым выявлением заболевания на поздних стадиях, а также с крайне низкой эффективностью лечения на этапе развития резистентности к препаратам платины. Применение иммунотерапии в данном случае не является стандартной опцией, однако в литературе описывается несколько исследований ранних фаз, посвященных ее потенциальной эффективности. В приведенном клиническом примере представлен успешный опыт использования ингибиторов контрольных точек иммунитета у предлеченной пациентки с платино-резистентным метастатическим раком яичников, сопровождавшийся различными иммуноопосредованными нежелательными явлениями.

Ovarian cancer is a serious problem in clinical oncology due to the frequent detection of the disease in late stages, as well as the extremely low effectiveness of treatment at the stage of development of resistance to platinum drugs. The use of immunotherapy in this setting is not a standard option, but several early phase trials of its potential effectiveness are described in the literature. This clinical case presents a successful experience with the use of immune checkpoint inhibitors in a pretreated patient with platinum-resistant metastatic ovarian cancer, which was accompanied by various immune-related adverse events.

рак яичниковиммунотерапияингибиторы контрольных точекиммуноопосредованные нежелательные явленияovarian cancerimmunotherapycheckpoint inhibitorsimmune-mediated adverse eventsReferencesBowtell D.D., Böhm S., Ahmed A.A. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer // Nat. Rev. Cancer. 2015. Vol. 15. Р. 668–679. doi: 10.1038/nrc4019.Bowtell D.D., Böhm S., Ahmed A.A. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer // Nat. Rev. Cancer. 2015. Vol. 15. Р. 668–679. doi: 10.1038/nrc4019.Cannistra S.A. Cancer of the ovary // N. Engl. J. Med. 2004. Vol. 351. Р. 2519–2529. doi: 10.1056/NEJMra041842.Cannistra S.A. Cancer of the ovary // N. Engl. J. Med. 2004. Vol. 351. Р. 2519–2529. doi: 10.1056/NEJMra041842.Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer. J. Clin. 2021. Vol. 71. Р. 209–249. doi: 10.3322/caac.21660.Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer. J. Clin. 2021. Vol. 71. Р. 209–249. doi: 10.3322/caac.21660.Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial // Lancet Oncol. 2014. Vol. 15. Р. 852–861. doi: 10.1016/S1470-2045(14)70228-1.Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial // Lancet Oncol. 2014. Vol. 15. Р. 852–861. doi: 10.1016/S1470-2045(14)70228-1.Ahmed A.A., Etemadmoghadam D., Temple J. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary // J. Pathol. 2010. Vol. 221. Р. 49–56. doi: 10.1002/path.2696.Ahmed A.A., Etemadmoghadam D., Temple J. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary // J. Pathol. 2010. Vol. 221. Р. 49–56. doi: 10.1002/path.2696.Lheureux S., Gourley C., Vergote I. et al. Epithelial ovarian cancer // Lancet. 2019. Vol. 393. Р. 1240–1253. doi: 10.1016/S0140-6736(18)32552-2.Lheureux S., Gourley C., Vergote I. et al. Epithelial ovarian cancer // Lancet. 2019. Vol. 393. Р. 1240–1253. doi: 10.1016/S0140-6736(18)32552-2.Armstrong D.K., Alvarez R.D., Bakkum-Gamez J.N. et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology // J. Natl. Compr. Canc. Netw. 2021. Vol. 19. Р. 191–226. doi: 10.6004/jnccn.2021.0007.Armstrong D.K., Alvarez R.D., Bakkum-Gamez J.N. et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology // J. Natl. Compr. Canc. Netw. 2021. Vol. 19. Р. 191–226. doi: 10.6004/jnccn.2021.0007.Siminiak N., Czepczyński R., Zaborowski M.P., Iżycki D. Immunotherapy in Ovarian Cancer // Arch. Immunol. Ther. Exp. (Warsz). 2022. Aug. 9; Vol. 70, No. 1. Р. 19. doi: 10.1007/s00005-022-00655-8.Siminiak N., Czepczyński R., Zaborowski M.P., Iżycki D. Immunotherapy in Ovarian Cancer // Arch. Immunol. Ther. Exp. (Warsz). 2022. Aug. 9; Vol. 70, No. 1. Р. 19. doi: 10.1007/s00005-022-00655-8.Katsumata N., Yasuda M., Isonishi S. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial // Lancet Oncol. 2013. Vol. 14. Р. 1020–1026. doi: 10.1016/S1470-2045(13)70363-2.Katsumata N., Yasuda M., Isonishi S. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial // Lancet Oncol. 2013. Vol. 14. Р. 1020–1026. doi: 10.1016/S1470-2045(13)70363-2.Wright A.A., Bohlke K., Armstrong D.K. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline // J. Gynecol. Oncol. 2016. Vol. 34. Р. 3460–3473.Wright A.A., Bohlke K., Armstrong D.K. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline // J. Gynecol. Oncol. 2016. Vol. 34. Р. 3460–3473.Poveda A.M., Selle F., Hilpert F. et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized Phase III AURELIA trial // J. Clin. Oncol. 2015. Vol. 3. Р. 3836–3838. doi: 10.1200/JCO.2015.63.1408.Poveda A.M., Selle F., Hilpert F. et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized Phase III AURELIA trial // J. Clin. Oncol. 2015. Vol. 3. Р. 3836–3838. doi: 10.1200/JCO.2015.63.1408.González-Martín A., Pothuri B., Vergote I. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer // N. Engl. J. Med. 2019. Vol. 381. Р. 2391–2402. doi: 10.1056/NEJMoa1910962.González-Martín A., Pothuri B., Vergote I. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer // N. Engl. J. Med. 2019. Vol. 381. Р. 2391–2402. doi: 10.1056/NEJMoa1910962.Moore K., Colombo N., Scambia G. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer // N. Engl. J. Med. 2018. Vol. 379. Р. 2495–2505. doi: 10.1056/NEJMoa1810858.Moore K., Colombo N., Scambia G. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer // N. Engl. J. Med. 2018. Vol. 379. Р. 2495–2505. doi: 10.1056/NEJMoa1810858.Ray-Coquard I., Pautier P., Pignata S. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer // N. Engl. J. Med. 2019. Vol. 381. Р. 2416–2428. doi: 10.1056/NEJMoa1911361.Ray-Coquard I., Pautier P., Pignata S. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer // N. Engl. J. Med. 2019. Vol. 381. Р. 2416–2428. doi: 10.1056/NEJMoa1911361.Matulonis U.A. Ovarian cancer // Hematol. Oncol. Clin. N. Am. 2018. Vol. 32, No. 6. Р. XIII–XIV. doi: 10.1016/j.hoc.2018.09.006.Matulonis U.A. Ovarian cancer // Hematol. Oncol. Clin. N. Am. 2018. Vol. 32, No. 6. Р. XIII–XIV. doi: 10.1016/j.hoc.2018.09.006.Levinson K., Dorigo O., Rubin K. et al. Immunotherapy in gynecologic cancers: what we know now and where we are headed // Am. Soc. Clin. Oncol. Educ. Book. 2019. Vol. 39. e126–e140. doi: 10.1200/EDBK_237967.Levinson K., Dorigo O., Rubin K. et al. Immunotherapy in gynecologic cancers: what we know now and where we are headed // Am. Soc. Clin. Oncol. Educ. Book. 2019. Vol. 39. e126–e140. doi: 10.1200/EDBK_237967.Lynam S., Lugade A.A., Odunsi K. Immunotherapy for gynecologic cancer: current applications and future directions // Clin. Obstetrics Gynecol. 2020. Vol. 63. Р. 48–63. doi: 10.1097/GRF.0000000000000513.Lynam S., Lugade A.A., Odunsi K. Immunotherapy for gynecologic cancer: current applications and future directions // Clin. Obstetrics Gynecol. 2020. Vol. 63. Р. 48–63. doi: 10.1097/GRF.0000000000000513.Brahmer J.R., Tykodi S.S., Chow L.Q.M. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancers // N. Engl. J. Med. 2012. Vol. 366, No. 26. Р. 2455–2465. doi: 10.1056/NEJMoa1200694.Brahmer J.R., Tykodi S.S., Chow L.Q.M. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancers // N. Engl. J. Med. 2012. Vol. 366, No. 26. Р. 2455–2465. doi: 10.1056/NEJMoa1200694.Awada A., Ahmad S., McKenzie N.D., Holloway R.W. Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives // Onco Targets Ther. 2022. Vol. 10, No. 15. Р. 853–866. doi: 10.2147/OTT.S335936.Awada A., Ahmad S., McKenzie N.D., Holloway R.W. Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives // Onco Targets Ther. 2022. Vol. 10, No. 15. Р. 853–866. doi: 10.2147/OTT.S335936.Matulonis U.A., Shapira-Frommer R., Santin A.D. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study // Ann. Oncol. 2019. Vol. 30, No. 7. Р. 1080–1087. doi: 10.1093/annonc/mdz135Matulonis U.A., Shapira-Frommer R., Santin A.D. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study // Ann. Oncol. 2019. Vol. 30, No. 7. Р. 1080–1087. doi: 10.1093/annonc/mdz135Zamarin D., Burger R.A., Sill M.W. et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study // J. Clin. Oncol. 2020. Vol. 38, No. 16. Р. 1814–1823. doi: 10.1200/JCO.19.02059.Zamarin D., Burger R.A., Sill M.W. et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study // J. Clin. Oncol. 2020. Vol. 38, No. 16. Р. 1814–1823. doi: 10.1200/JCO.19.02059.Wang L. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study // J. Ovarian. Res. 2019. Vol. 12. Р. 37. doi: 10.1186/s13048-019-0512-6.Wang L. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study // J. Ovarian. Res. 2019. Vol. 12. Р. 37. doi: 10.1186/s13048-019-0512-6.Pawłowska A., Kwiatkowska A., Suszczyk D. et al. Clinical and prognostic value of antigen-presenting cells with PD- L1/PD-L2 expression in ovarian cancer patients // Int. J. Mol. Sci. 2021. Vol. 22. Р. 11563. doi: 10.3390/ijms222111563.Pawłowska A., Kwiatkowska A., Suszczyk D. et al. Clinical and prognostic value of antigen-presenting cells with PD- L1/PD-L2 expression in ovarian cancer patients // Int. J. Mol. Sci. 2021. Vol. 22. Р. 11563. doi: 10.3390/ijms222111563.Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized Phase 1 clinical trial // JAMA Oncol. 2020. Vol. 6. Р. 1766–1772. doi: 10.1001/jamaoncol.2020.4515.Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: a nonrandomized Phase 1 clinical trial // JAMA Oncol. 2020. Vol. 6. Р. 1766–1772. doi: 10.1001/jamaoncol.2020.4515.Bonneville R., Krook M.A., Kautto E.A. et al. Landscape of microsatellite instability across 39 cancer types // CO Precis Oncol. 2017. Vol. 2017. PO.17.00073. doi: 10.1200/PO.17.00073.Bonneville R., Krook M.A., Kautto E.A. et al. Landscape of microsatellite instability across 39 cancer types // CO Precis Oncol. 2017. Vol. 2017. PO.17.00073. doi: 10.1200/PO.17.00073.Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2013. Vol. 24, Suppl. 6. vi24–32. doi: 10.1093/annonc/mdt333.Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C.; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2013. Vol. 24, Suppl. 6. vi24–32. doi: 10.1093/annonc/mdt333.

The authors declare that there are no conflicts of interest present.